SLS Sellas Life Sciences Group Inc

SEELAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications.

As of 10/05/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/11/2013
Outstanding shares:  20,551,918
Average volume:  100,891
Market cap:   $41,514,874
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -2.00
PB ratio:   8.22
PS ratio:   14.32
Return on equity:   -870.56%
Net income %:   -1,208.28%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy